RegulatoryLast verified: 2026-05-02
FDA Finalizes Reclassification of Seven Compounded Peptides, April 2026
FDA finalized the reclassification of seven peptides previously available through 503A compounding pharmacies. BPC-157, TB-500, KPV, DSIP, Epitalon, LL-37, Selank, Semax, and Melanotan II are no longer eligible for traditional compounding. Advisory panel for remaining peptides scheduled July 2026.
bpc-157tb-500kpvdsipepitalonll-37selanksemaxmelanotan-iifda-reclassificationcompoundingregulation
Read →Reclassification pending